Justin Sparkes, DO
Internal Medicine · Edmond, OKNPI 1265487946
Payments from drug & device makers
Across 183 payments — averaging $14.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$772
- AbbVie$490
- GSK$259
- AstraZeneca$197
- Novo Nordisk$192
- Amgen$111
- plus $704 from 18 others
What the payments were for
- Food & beverage$2,714100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 59 | $772 |
| AbbVie(2 entities) | 24 | $490 |
| GSK | 19 | $259 |
| AstraZeneca | 14 | $197 |
| Novo Nordisk | 15 | $192 |
| Amgen | 7 | $111 |
| Astellas Pharma US Inc | 8 | $106 |
| Dexcom, Inc. | 5 | $77 |
| Lilly USA, LLC | 4 | $71 |
| Amarin Pharma, Inc. | 4 | $48 |
| Shield Therapeutics Inc | 1 | $44 |
| Organon | 3 | $44 |
| Merck | 3 | $43 |
| Abbott | 2 | $41 |
| Johnson & Johnson | 3 | $35 |
| Sanofi Pasteur Inc. | 2 | $33 |
| Boehringer Ingelheim | 2 | $29 |
| Pulmonx Corporation | 1 | $26 |
| Nalpropion Pharmaceuticals LLC | 2 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Bayer | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
How this compares
$2,725 in reported general payments places this provider in the 80th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 178 | $179,320 |
| EliquisApixaban | 119 | $138,047 |
| OzempicSemaglutide | 100 | $117,795 |
| TrulicityDulaglutide | 76 | $101,629 |
| MounjaroTirzepatide | 81 | $87,205 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $60,030 |
| MyrbetriqMirabegron | 72 | $37,924 |
| JanuviaSitagliptin Phosphate | 31 | $31,875 |
| FarxigaDapagliflozin Propanediol | 35 | $29,951 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 27 | $29,032 |
| XareltoRivaroxaban | 41 | $25,952 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $22,561 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $21,694 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $20,971 |
| ProliaDenosumab | 12 | $20,427 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr | $29 | $198,414189 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $71 | $188,834157 claims |
| PfizerEliquis | $772 | $138,047119 claims |
| Novo NordiskOzempic, Xultophy 100-3.6 | $192 | $137,724113 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $259 | $81,001138 claims |
| Astellas Pharma US IncMyrbetriq | $106 | $37,92472 claims |
| AstraZenecaFarxiga, Symbicort | $197 | $34,23555 claims |
| MerckJanuvia | $43 | $31,87531 claims |
| Johnson & JohnsonXarelto | $35 | $25,95241 claims |
| AmgenProlia | $111 | $20,42712 claims |
| AbbVieLinzess | $490 | $11,32520 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $14 | $6,46712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Edmond
- Todd KrehbielEdmond$21K
- Ashlee WaughEdmond$15K
- William MorganEdmond$13K
- Thomas KupiecEdmond$12K
- Al-Ola AbdallahTulsa$10.1M
- Melita TateTulsa$9.1M
- Sagila GeorgeOklahoma City$1.8M
- Ryan MorganOklahoma City$775K
- Renae MayerTulsa$766K
- George FreemanIdabel$742K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.